Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ioglucomide: a new nonionic myelographic agent. Preclinical studies

R M Hopkins, M D Adams, D H Lau

    Radiology
    |September 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.

    British journal of cancer·2014
    Same author

    Trends in the use of implantable cardioverter defibrillators in Australia: a 10-year nationwide study from 2000-2009.

    Internal medicine journal·2013
    Same author

    Automated quantification of atrial fibrillation complexity by probabilistic electrogram analysis and fibrillation wave reconstruction.

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2013
    Same author

    The malaria genome sequencing project.

    Protist·2012
    Same author

    Evidence-based management of heart failure in clinical practice: a review of device-based therapy use.

    Internal medicine journal·2009
    Same author

    Longitudinal myelitis, aseptic meningitis, and conus medullaris infarction as presenting manifestations of pediatric systemic lupus erythematosus.

    Lupus·2008
    Same journal

    Erratum for: Prediction of Lobar Emphysema Progression with a CT-Based Foundational Model.

    Radiology·2026
    Same journal

    Erratum for: Associations of MRI-derived Paraspinal IMAT and LMM with Cardiometabolic Risk Factors: Results from a German Cohort.

    Radiology·2026
    Same journal

    Erratum for: Blue Rubber Bleb Nevus Syndrome.

    Radiology·2026
    Same journal

    Redefining the Clinical Role of MRI in Endometrial Cancer Staging.

    Radiology·2026
    Same journal

    To Ablate or Not to Ablate: The Colorectal Liver Metastasis Question.

    Radiology·2026
    Same journal

    The Limits of Radiologic Categorization in Pulmonary Nonsolid Nodules.

    Radiology·2026
    See all related articles

    Ioglucomide, a novel iodinated nonionic contrast agent, demonstrated superior safety over metrizamide in animal toxicological studies, showing reduced acute toxicity and no convulsive activity. Its enhanced safety profile may not be linked to osmolality.

    Area of Science:

    • Radiology
    • Pharmacology
    • Toxicology

    Background:

    • Iodinated nonionic contrast media are crucial for myelography.
    • Metrizamide has been a standard agent, but its safety profile has limitations.

    Purpose of the Study:

    • To evaluate the toxicological profile of ioglucomide, a new contrast medium for myelography.
    • To compare the safety of ioglucomide with metrizamide in preclinical animal models.

    Main Methods:

    • Extensive toxicological examination of ioglucomide in animals.
    • Direct comparison of ioglucomide and metrizamide in various toxicity assessments.
    • Evaluation of acute toxicity after intravenous injection and cerebrospinal fluid instillation.
    • Assessment of subarachnoid administration effects, including convulsive activity.

    Related Experiment Videos

    Main Results:

    • Ioglucomide and metrizamide showed comparable efficacy in preventing arachnoiditis.
    • Ioglucomide exhibited significantly lower acute toxicity than metrizamide via intravenous and cerebrospinal fluid routes.
    • Subarachnoid administration of ioglucomide did not induce any convulsive activity, unlike metrizamide.
    • The enhanced safety of ioglucomide was not attributable to its osmolality.

    Conclusions:

    • Ioglucomide presents an improved safety profile compared to metrizamide for myelographic use.
    • The findings question the primary role of osmolality in the safety of nonionic myelographic agents.
    • Ioglucomide represents a promising alternative contrast medium for myelography due to its enhanced safety characteristics.